Embecta Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 0/6
Embecta şirketinin toplam hissedar öz sermayesi $-612.7M ve toplam borcu $1.5B olup, bu da borç-öz sermaye oranını -237.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $1.3B ve $1.9B dir. Embecta 'in FAVÖK'ü $237.3M faiz karşılama oranı 2.5 dur. Şirketin $214.7M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
-237.49%
Borç/özkaynak oranı
US$1.46b
Borç
| Faiz karşılama oranı | 2.5x |
| Nakit | US$214.70m |
| Eşitlik | -US$612.70m |
| Toplam yükümlülükler | US$1.88b |
| Toplam varlıklar | US$1.27b |
Son finansal sağlık güncellemeleri
Recent updates
Seeking Alpha • Aug 25
The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products
Summary Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC's high gross margins (59.6%) and market leadership position support a bullish 12-month target of $8-10 per share. Technical momentum has turned positive, with insider buying and extended short interest setting up the potential for a sharp rebound if fundamentals stabilize. I rate EMBC a Buy under $7, with Strong Buy territory pegged below $4, citing takeover potential and defensive sector appeal amid market rotation. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 14
EMBC: Wound Care Expansion Will Support Future Upside Despite Legal And Medtech Headwinds
Analysts have cut their Embecta price targets sharply, with one key target moving from $11 to $3 as they factor in weaker medtech sentiment, concerns about utilization and inflation, and a shift in investor focus toward data centers instead of healthcare. Analyst Commentary Recent research on Embecta highlights a sharp reset in expectations as analysts reassess the stock against a tougher backdrop for medtech valuations, higher inflation, and investor interest shifting toward data centers.
Anlatı Güncellemesi • Jun 29
EMBC: Medtech Repricing And Index Removals Will Pressure Future Returns
Analysts have reduced their price target for Embecta to $3 from $11, citing updated views on medtech valuations, regulatory and utilization concerns, and a reset in expectations for revenue growth, profit margins, and forward P/E multiples. Analyst Commentary Recent Street research on Embecta points to a more cautious stance, with multiple bearish analysts trimming price targets and reassessing the stock in light of sector wide pressures in medical technology and concerns around utilization and regulation.
Anlatı Güncellemesi • Jun 15
EMBC: Medtech Reset And Buybacks May Support Future Rebound Potential
Embecta's analyst price targets have been sharply reset lower, with one major firm cutting its view to $3 from $11 as analysts factor in what they see as tougher medtech valuations tied to slower product cycles, healthcare utilization concerns, inflation pressures after recent conflicts, and investor preference for data center exposure over healthcare. Analyst Commentary Recent research commentary around Embecta has centered on recalibrating expectations for medtech stocks in light of slower product cycles, healthcare utilization questions, and cost pressures tied to inflation.Anlatı Güncellemesi • Jun 01
EMBC: Sector Reset And Buybacks Will Shape Future Upside Potential
The Street’s view on Embecta has reset sharply, with the average analyst price target moving from about $11 to around $5 as analysts recalibrate for lower P/E assumptions and sector wide pressure on medtech valuations. This pressure is tied to slower product cycles, utilization concerns, higher inflation, and capital flowing to data centers instead of healthcare.Anlatı Güncellemesi • May 16
EMBC: Reset Expectations And Capital Returns Will Shape The Bullish Case
Analysts have reset Embecta's fair value estimate from $25 to $11, reflecting lower price targets after recent cuts from firms that cited updated views on growth, profitability and risk. Analyst Commentary Recent research updates point to a more cautious stance on Embecta's valuation, with several firms lowering their price targets and, in at least one case, issuing a downgrade.Anlatı Güncellemesi • Apr 30
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.Anlatı Güncellemesi • Apr 15
EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Anlatı Güncellemesi • Feb 18
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).Analiz Makalesi • Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...Analiz Makalesi • Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 2.4% to close at US$10.87 following the...Analiz Makalesi • Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...Anlatı Güncellemesi • Feb 03
EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.Anlatı Güncellemesi • Jan 20
EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.Analiz Makalesi • Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...Anlatı Güncellemesi • Jan 05
EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).Anlatı Güncellemesi • Dec 15
EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.Analiz Makalesi • Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
It's been a sad week for Embecta Corp. ( NASDAQ:EMBC ), who've watched their investment drop 14% to US$12.57 in the...Analiz Makalesi • Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it saw a significant share price rise of 36...Analiz Makalesi • Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for Embecta is US$27.21 based on 2 Stage Free Cash Flow to Equity Embecta's...Analiz Makalesi • Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Despite an already strong run, Embecta Corp. ( NASDAQ:EMBC ) shares have been powering on, with a gain of 29% in the...Anlatı Güncellemesi • Aug 10
GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.Analiz Makalesi • Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 11.4x might make it look like a buy right now...Analiz Makalesi • May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Analiz Makalesi • May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...Analiz Makalesi • Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Key Insights Embecta's estimated fair value is US$24.29 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • Feb 28
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Summary Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. However, the expanding diabetes care market should partially offset these headwinds, leading to flat topline growth in the coming years. Even though the company is going to post a flat topline, its valuation is such that the business is going to go bust in some time. This situation offers a good risk reward to go long on the stock. Read the full article on Seeking AlphaSeeking Alpha • Dec 04
New Initiatives Expected To Make Embecta More Profitable
Summary Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. I have upgraded the rating on EMBC stock to a Buy, expecting a 12.0% share price increase over the next year, driven by restructuring and new revenue streams. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Embecta Corp. ( NASDAQ:EMBC ) will pay a dividend of $0.15 on the 18th of December. The dividend yield will be 2.9...Analiz Makalesi • Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Analiz Makalesi • Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 12.6x might make it look like a buy right now...
Yeni Anlatı • Sep 16
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: EMBC negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.
Uzun Vadeli Yükümlülükler: EMBC şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: EMBC negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.
Borcun Azaltılması: EMBC 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.
Borç Kapsamı: EMBC 'nin borcu işletme nakit akışı ( 12% ) tarafından iyi bir şekilde karşılanmıyor.
Faiz Kapsamı: EMBC 'in borcuna ilişkin faiz ödemeleri EBIT ( 2.5 x kapsam) tarafından iyi karşılanmıyor.
Bilanço
Sağlıklı şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/12 21:48 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/09/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Embecta Corp. 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |